Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Paul G. Richardson, Constantine Mitsiades, Kathleen Colson, +11

Leukemia & lymphoma/Leukemia and lymphoma

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Paul G. Richardson, David S. Siegel, Rachid Baz, +19

Blood

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David S. Siegel, Rachid Baz, +9

Blood

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

David H. Vesole, Elizabeth Bilotti, Joshua Richter, +13

British Journal of Haematology

Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats

Nirupama Laroia, Laura McBride, Raymond B. Baggs, +1

Developmental Brain Research

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, +11

Blood

The Anion Gap and Routine Serum Protein Measurements in Monoclonal Gammopathies

Karen H. van Hoeven, Rosy E. Joseph, William J. Gaughan, +6

Clinical Journal of the American Society of Nephrology

Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies

D. S. Siegel, Laura McBride, Elizabeth Bilotti, +7

Laboratory Medicine

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Joshua R. Richter, Elizabeth Bilotti, Laura McBride, +9

Blood

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens

Larysa Sanchez, David H. Vesole, Joshua Richter, +6

British Journal of Haematology